Clinical advances of RNAi therapy discussed at Oligonucleotide Therapeutics and Delivery Conference

SMi reports: Discussions will be centered around improving targeted therapy uniting the field's biggest players to share their opinions
By: SMi Group
 
 
1200x627
1200x627
LONDON - June 17, 2021 - PRLog -- From optimizing particle size to choosing the right nanocarrier systems, Oligonucleotide Therapeutics and Delivery conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms.

Download a copy of your brochure to find out who will be speaking at the upcoming conference in September www.oligonucleotide.co.uk/prlog4

CLINICAL ADVANCES OF RNAI THERAPY

Treating diseases with antibody oligonucleotide conjugates: Combining the selectivity of antibodies with the specificity of oligonucleotide drugs
  • Antibody oligonucleotide conjugates utilize the selectivity of antibody delivery and the specificity of oligonucleotide therapeutics to treat diseases
  • AOC1001 is designed to treat myotonic dystrophy type 1
  • Other AOCs are in development to address muscle disease and other disorders

Arthur A Levin, Chief Scientific Officer, Avidity Biosciences Inc

Delivery of Novel siRNA constructs for treating cancer
  • Creating siRNA payloads for cancer treatment
  • Understanding the challenges of cell-specific delivery: how to get size and efficacy right?
  • Choosing the appropriate delivery system
  • Presenting success and future steps

David Evans, Chief Scientific Officer, Sirnaomics, Inc

Recent clinical progress with RNAi loaded KRAS-LODER for pancreatic tumour
  • Introducing the RNAi loaded KRAS-LODER for targeting KRAS mutations
  • Overviewing recent clinical success in phase II trials
  • Presenting phase II clinical trials results including primary and secondary endpoints
  • Outlining next steps of programme

Amotz Shemi, CEO, Silenseed
INT-1B3 (miR-193a-3p mimic): from bench-to-bedside
  • Focus on microRNA R&D
  • Success (bench-to-bedside) story for Oncology therapeutic intervention
  • Preclinical to first in human study transition

Michel Janicot, CDO, InteRNA Technologies BV

Register online: www.oligonucleotide.co.uk/prlog4
Early bird offer register by 30th June and save £100

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For more details and all delegate enquiries please contact Alia Malick on: +44 (0)20 7827 6168.

For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088.

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Contact
Jinna Sidhu
***@smi-online.co.uk
End
Email:***@smi-online.co.uk
Posted By:***@smi-online.co.uk Email Verified
Tags:#SMiOligonucleotides
Industry:Health
Location:London City - London, Greater - England
Subject:Features
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share